PRME
NASDAQ · Biotechnology
Prime Medicine Inc
$3.52
-0.16 (-4.35%)
Open$3.69
Previous Close$3.68
Day High$3.77
Day Low$3.52
52W High$6.94
52W Low$1.11
Volume—
Avg Volume2.11M
Market Cap601.10M
P/E Ratio—
EPS$-1.44
SectorBiotechnology
Analyst Ratings
Buy
17 analysts
Price Target
+1,127.0% upside
Current
$3.52
$3.52
Target
$43.19
$43.19
$33.60
$43.19 avg
$71.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.60M | 5.54M | 80.41M |
| Net Income | -301,756,085 | -327,047,779 | -21,315,556 |
| Profit Margin | -6,566.6% | -6,238.3% | -26.5% |
| EBITDA | -302,395,553 | -345,948,669 | -26,154,771 |
| Free Cash Flow | — | — | -13,660,015 |
| Rev Growth | -17.0% | -17.0% | +23.7% |
| Debt/Equity | — | — | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |